Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases :: multicentre study of 80 patients

José Luis Martín-Varillas; Lara Sanchez-Bilbao; Vanesa Calvo-Río; Alfredo Adan Civera; Inés Hernanz; Adela Gallego-Flores; Emma Beltran Catalan; Sonia Castro-Oreiro; Patricia Fanlo; Alvaro Garcia Martos; Ignacio Torre; Miguel Cordero-Coma; Juan Ramon De Dios; Ángel García-Aparicio; Marisa Hernández-Garfella; Amalia Sánchez-Andrade; Andrea García-Valle; Olga Maiz; Roberto Miguélez; Sergio Rodríguez-Montero; A Urruticoechea-Arana; Raúl Veroz; Arantxa Conesa; Cristina Fernández-Carballido; Vega Jovaní; Jose J. Mondejar; Olga Martínez González; Patricia Moya; Susana Romero-Yuste; Paula Rubio-Muñoz; Eva Peña-Sainz-Pardo; Marta Garijo-Bufort; Rosalía Demetrio-Pablo; José Luis Hernández; Ricardo Blanco

doi:10.1136/rmdopen-2022-002693

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases : multicentre study of 80 patients

José Luis Martín-Varillas, Lara Sanchez-Bilbao, Vanesa Calvo-Río, Alfredo Adan Civera, Inés Hernanz, Adela Gallego-Flores, Emma Beltran Catalan, Sonia Castro-Oreiro, Patricia Fanlo, Alvaro Garcia Martos, Ignacio Torre, Miguel Cordero-Coma, Juan Ramon De Dios, Ángel García-Aparicio, Marisa Hernández-Garfella, Amalia Sánchez-Andrade, Andrea García-Valle, Olga Maiz, Roberto Miguélez, Sergio Rodríguez-MonteroA Urruticoechea-Arana, Raúl Veroz, Arantxa Conesa, Cristina Fernández-Carballido, Vega Jovaní, Jose J. Mondejar, Olga Martínez González, Patricia Moya, Susana Romero-Yuste, Paula Rubio-Muñoz, Eva Peña-Sainz-Pardo, Marta Garijo-Bufort, Rosalía Demetrio-Pablo, José Luis Hernández, Ricardo Blanco

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

9 Cites (Scopus)

Resum

Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.

Idioma original	Anglès
Revista	RMD Open
Volum	8
Número	2
DOIs	https://doi.org/10.1136/rmdopen-2022-002693
Estat de la publicació	Publicada - 2022

Accés al document

10.1136/rmdopen-2022-002693

https://ddd.uab.cat/record/283219

Com citar-ho

Martín-Varillas, J. L., Sanchez-Bilbao, L., Calvo-Río, V., Adan Civera, A., Hernanz, I., Gallego-Flores, A., Beltran Catalan, E., Castro-Oreiro, S., Fanlo, P., Garcia Martos, A., Torre, I., Cordero-Coma, M., De Dios, J. R., García-Aparicio, Á., Hernández-Garfella, M., Sánchez-Andrade, A., García-Valle, A., Maiz, O., Miguélez, R., ... Blanco, R. (2022). Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases : multicentre study of 80 patients. RMD Open, 8(2). https://doi.org/10.1136/rmdopen-2022-002693

@article{c0a2ef1f95004189bc78e3e8f7acd9c3,

title = "Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases :: multicentre study of 80 patients",

abstract = "Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Beh{\c c}et's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.",

author = "Mart{\'i}n-Varillas, {Jos{\'e} Luis} and Lara Sanchez-Bilbao and Vanesa Calvo-R{\'i}o and {Adan Civera}, Alfredo and In{\'e}s Hernanz and Adela Gallego-Flores and {Beltran Catalan}, Emma and Sonia Castro-Oreiro and Patricia Fanlo and {Garcia Martos}, Alvaro and Ignacio Torre and Miguel Cordero-Coma and {De Dios}, {Juan Ramon} and {\'A}ngel Garc{\'i}a-Aparicio and Marisa Hern{\'a}ndez-Garfella and Amalia S{\'a}nchez-Andrade and Andrea Garc{\'i}a-Valle and Olga Maiz and Roberto Migu{\'e}lez and Sergio Rodr{\'i}guez-Montero and A Urruticoechea-Arana and Ra{\'u}l Veroz and Arantxa Conesa and Cristina Fern{\'a}ndez-Carballido and Vega Jovan{\'i} and Mondejar, {Jose J.} and {Mart{\'i}nez Gonz{\'a}lez}, Olga and Patricia Moya and Susana Romero-Yuste and Paula Rubio-Mu{\~n}oz and Eva Pe{\~n}a-Sainz-Pardo and Marta Garijo-Bufort and Rosal{\'i}a Demetrio-Pablo and Hern{\'a}ndez, {Jos{\'e} Luis} and Ricardo Blanco",

year = "2022",

doi = "10.1136/rmdopen-2022-002693",

language = "English",

volume = "8",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "2",

}

Martín-Varillas, JL, Sanchez-Bilbao, L, Calvo-Río, V, Adan Civera, A, Hernanz, I, Gallego-Flores, A, Beltran Catalan, E, Castro-Oreiro, S, Fanlo, P, Garcia Martos, A, Torre, I, Cordero-Coma, M, De Dios, JR, García-Aparicio, Á, Hernández-Garfella, M, Sánchez-Andrade, A, García-Valle, A, Maiz, O, Miguélez, R, Rodríguez-Montero, S, Urruticoechea-Arana, A, Veroz, R, Conesa, A, Fernández-Carballido, C, Jovaní, V, Mondejar, JJ, Martínez González, O, Moya, P, Romero-Yuste, S, Rubio-Muñoz, P, Peña-Sainz-Pardo, E, Garijo-Bufort, M, Demetrio-Pablo, R, Hernández, JL & Blanco, R 2022, 'Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases : multicentre study of 80 patients', RMD Open, vol. 8, núm. 2. https://doi.org/10.1136/rmdopen-2022-002693

TY - JOUR

T1 - Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases :

T2 - multicentre study of 80 patients

AU - Martín-Varillas, José Luis

AU - Sanchez-Bilbao, Lara

AU - Calvo-Río, Vanesa

AU - Adan Civera, Alfredo

AU - Hernanz, Inés

AU - Gallego-Flores, Adela

AU - Beltran Catalan, Emma

AU - Castro-Oreiro, Sonia

AU - Fanlo, Patricia

AU - Garcia Martos, Alvaro

AU - Torre, Ignacio

AU - Cordero-Coma, Miguel

AU - De Dios, Juan Ramon

AU - García-Aparicio, Ángel

AU - Hernández-Garfella, Marisa

AU - Sánchez-Andrade, Amalia

AU - García-Valle, Andrea

AU - Maiz, Olga

AU - Miguélez, Roberto

AU - Rodríguez-Montero, Sergio

AU - Urruticoechea-Arana, A

AU - Veroz, Raúl

AU - Conesa, Arantxa

AU - Fernández-Carballido, Cristina

AU - Jovaní, Vega

AU - Mondejar, Jose J.

AU - Martínez González, Olga

AU - Moya, Patricia

AU - Romero-Yuste, Susana

AU - Rubio-Muñoz, Paula

AU - Peña-Sainz-Pardo, Eva

AU - Garijo-Bufort, Marta

AU - Demetrio-Pablo, Rosalía

AU - Hernández, José Luis

AU - Blanco, Ricardo

PY - 2022

Y1 - 2022

N2 - Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.

AB - Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.

U2 - 10.1136/rmdopen-2022-002693

DO - 10.1136/rmdopen-2022-002693

M3 - Article

C2 - 36597972

SN - 2056-5933

VL - 8

JO - RMD Open

JF - RMD Open

IS - 2

ER -

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases : multicentre study of 80 patients

Resum

Accés al document

Fingerprint

Com citar-ho